http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Alex M. Azar II Joins Guardant Health Board of Directors
-
Guardant Health Expands Access to Shield CRC Blood Test to Senior Living Communities with LabFlorida Partnership
-
Guardant Health partners with PathGroup to expand Shield blood test access
-
Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States
-
Guardant Health reports improved Shield cancer test performance
-
Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test
-
Guardant Health to Host Investor Day on September 24, 2025
-
Guardant Health to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
-
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
American Cancer Society and Guardant Health Partner to Expand Cancer Screening Access and Advance Health Equity
-
Guardant Health to Participate in the Canaccord Genuity 45th Annual Growth Conference
-
Guardant Health Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
-
Guardant Health and James Van Der Beek Team Up to Raise Awareness About New Advances in Colorectal Cancer Screening for Adults 45+
-
New RADIOHEAD Study Validates Use of Guardant Reveal Tissue-Free Monitoring for Earlier Detection of Immunotherapy Response in Advanced Cancer
-
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test
-
Guardant Health to Report Second Quarter 2025 Financial Results on July 30, 2025
-
Guardant Health Wins Fast Company’s 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening
-
New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer
-
Guardant Health (GH) Granted FDA Breakthrough Device Designation for Multi-Cancer Detection (MCD) Test
-
FDA Grants Breakthrough Device Designation to Guardant Health’s Shield Multi-Cancer Detection (MCD) Test
-
National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening
-
SERENA-6 Phase III Trial Demonstrates Clinical Value of Guardant360 CDx Test to Detect Emergence of Endocrine Resistance and Inform a Switch in Therapy Before Radiological Disease Progression in Advan
-
In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Ti
-
Guardant Health (GH) announces new features for Guardant 360 Liquid test
-
Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test
-
Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting
-
Guardant Health (GH) adds full suite of IHC testing
-
Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors
-
Guardant Health (GH) Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer
-
Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer
-
Guardant Health to Participate in Upcoming Investor Conferences
-
TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year
-
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
-
Guardant Health (GH) Presents Data Demonstrating Strong Performance of Shield Multi-Cancer Detection Test Across 10 Tumor Types
-
Guardant Health Presents Data Demonstrating Strong Performance of Shield Multi-Cancer Detection Test Across 10 Tumor Types
-
Guardant Health (GH) Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer
-
Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer
-
Guardant Health (GH) Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform
-
Guardant Health Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform
-
Guardant Health to Present Data Highlighting Advances in Multi-Cancer Detection and Liquid and Tissue Molecular Profiling at AACR
-
Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025
-
Guardant Health (GH) partners with Bayshore HealthCare to offer testing portfolio in Canada
-
Guardant Health and Bayshore HealthCare Partner to Expand Access to Advanced Precision Oncology Testing in Canada
-
Guardant Health's (GH) Shield Blood Test Now Covered for VA Community Care Beneficiaries
-
Guardant Health’s Shield Blood Test Now Covered for VA Community Care Beneficiaries
-
Guardant Health (GH) Receives ADLT Status From CMS for Shield Blood Test
-
Guardant Health Receives ADLT Status From CMS for Shield Blood Test
-
Guardant Health Joins Forces With Dak Prescott’s Faith Fight Finish Foundation and Feist-Weiller Cancer Center’s Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities
-
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

